Abstract
The association between malignancy and clinical thrombosis has been recognized for nearly 140 years. The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment.
Copyright 2002 Wiley-Liss, Inc.
MeSH terms
-
Algorithms
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use
-
Biomarkers
-
Catheterization, Central Venous / adverse effects
-
Cysteine Endopeptidases / metabolism
-
Diagnostic Imaging
-
Disseminated Intravascular Coagulation
-
Female
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
Incidence
-
Male
-
Neoplasm Proteins / metabolism
-
Neoplasms / blood
-
Neoplasms / complications*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Postoperative Complications / etiology
-
Thromboembolism / diagnosis
-
Thromboembolism / drug therapy
-
Thromboembolism / epidemiology
-
Thromboembolism / etiology*
-
Thromboembolism / prevention & control
-
Thrombophilia / diagnosis
-
Thrombophilia / epidemiology
-
Thrombophilia / etiology*
-
Venous Thrombosis / epidemiology
-
Venous Thrombosis / etiology
Substances
-
Anticoagulants
-
Biomarkers
-
Fibrinolytic Agents
-
Neoplasm Proteins
-
Platelet Aggregation Inhibitors
-
Cysteine Endopeptidases
-
cancer procoagulant